Kala Pharmaceuticals Inc. (KALA)
3.43
0.06 (1.78%)
At close: Apr 14, 2025, 12:51 PM
1.78% (1D)
| Bid | 3.42 |
| Market Cap | 22.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.51M |
| EPS (ttm) | -10.15 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -1.46 |
| Analyst | Buy |
| Ask | 3.58 |
| Volume | 38,760 |
| Avg. Volume (20D) | 61,359.9 |
| Open | 3.52 |
| Previous Close | 3.37 |
| Day's Range | 3.43 - 3.85 |
| 52-Week Range | 3.35 - 11.20 |
| Beta | -1.72 |
About KALA
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye ...
Sector Healthcare
IPO Date Jul 20, 2017
Employees 38
Stock Exchange NASDAQ
Ticker Symbol KALA
Website https://www.kalarx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for KALA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 337.32% from the latest price.
Stock Forecasts2 months ago
-31.62%
KALA BIO shares are trading lower after the compan...
Unlock content with
Pro Subscription
9 months ago
+40.22%
KALA BIO shares are trading higher. The company announced a $12.5 million private placement.
